drug

autogene cevumeran

1 story · latest Aug 28, 2026

Status: Investigational
Code: RO7198457
Trials: 2 registered trials in coverage

Relationships

Developed by Roche

Timeline

BioNTech ends Phase 2 trial of autogene cevumeran in colorectal cancer

Aug 28Clinical readoutautogene cevumeran BioNTech SE

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.